Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Acular LS Clear all
Completed Phase 4 Interventional

Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation

NCT00366691
View directory record Official record
Conditions
Cataract Extraction
Interventions
Acular LS, Lotemax
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement

NCT00621530
View directory record Official record
Conditions
Hip Arthroplasty
Interventions
ketorolac tromethamine opthalmic solution, placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma

NCT04495894
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions
Preoperative Ketorolac
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional

A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief

NCT00330798
View directory record Official record
Conditions
Photorefractive Keratectomy
Interventions
nepafenac 0.1%, ketorolac 0.4%
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)

NCT01769352
View directory record Official record
Conditions
Post-surgical Cystoid Macular Edema (PSCME)
Interventions
PredA + Kelac
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

NCT00791323
View directory record Official record
Conditions
Inflammation
Interventions
Ketorolac 0.4%, Lubricating Eye Drop
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

NCT00333255
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac Ophthalmic Suspension, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
10 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Nacogdoches, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2009 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects

NCT00469690
View directory record Official record
Conditions
Cataract
Interventions
Acular, Xibrom
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy

NCT00765128
View directory record Official record
Conditions
Renal Calculus, Kidney Stones
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

Nevanac 3-Month Safety Study With QID Dosing

NCT00332774
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac ophthalmic solution 0.1%, Ketorolac Tromethamine ophthalmic solution 0.4%, Nepafenac ophthalmic suspension vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
10 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2012 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular

NCT02242201
View directory record Official record
Conditions
Total Hip Arthroplasty
Interventions
PNB Bupivacaine, PAI Ropivacaine, PAI liposomal bupivacaine, Epinephrine, Ketorolac
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Spinal Ketorolac After Acute Opioid Exposure

NCT00693160
View directory record Official record
Conditions
Healthy
Interventions
ketorolac, placebo, remifentanil, Capsaicin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Not listed Phase 3 Interventional

Femoral Nerve Block Compared to Exparel in Total Knee Replacement

NCT02473198
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Exparel, Femoral Nerve Block Bupivacaine, Toradol, Morphine Sulfate
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
18 Years to 73 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated No phase listed Observational

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)

NCT01097447
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Not listed
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
2,619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Littleton, Colorado • Hoffman Estates, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated No phase listed Observational

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

NCT01189864
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicin or Vigamox or other., Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
12 Years and older
Enrollment
3,493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Laguna Hills, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 0.4% Ketorolac and Vitreoretinal Surgery

NCT00576329
View directory record Official record
Conditions
Surgery
Interventions
Ketorolac
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated No phase listed Observational

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01024322
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicine or Vigamox or other., Nonsteroidal (Acular, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Miami, Florida • Rockville, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

NCT01673191
View directory record Official record
Conditions
Macular Edema, Diabetes Mellitus
Interventions
Dexamethasone intravitreal implant, Steroid plus NSAID eye drop combination therapy
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy

NCT00765232
View directory record Official record
Conditions
Nephrectomy, Laparoscopic Donor Nephrectomy
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Sep 1, 2026, 10:42 AM EDT